Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “These positive results from the KEYNOTE-A18 trial demonstrate the potential of KEYTRUDA in combination with concurrent chemoradiotherapy as a...
KEYNOTE-811 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03615326) evaluating KEYTRUDA in combination with trastuzumab and chemotherapy for the first-line treatment of locally advanced unresectable ...
Elise AronitzEVERSANA, Burlington, ON, CanadaToby A. EyreOxford University Hospitals NHS Trust, Oxford, United KingdomMatthew Steven DavidsDana-Farber Cancer Institute, Boston, MAAmerican Society of Clinical OncologyJournal of Clinical Oncology
meaning that it was meant to really define whether or not lenvatinib was noninferior to sorafenib, in terms of the primary end point of OS and REFLECT certainly met that primary end point. The median OS for patients that were treated with lenvatinib in the REFLECT trial was 13.6 months. A...
Incidence of clinical malaria was 0·12 episodes per child-year in children in the unmodified houses and 0·20 episodes per child-year in the modified houses (unadjusted incidence rate ratio [RR] 1·68 [95% CI 1·11–2·55], p=0·014). Household vector density was 3·30 Anopheles ...